Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

BACKGROUND: Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the ‘preclinical’ stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Perrin, Richard J., Craig-Schapiro, Rebecca, Malone, James P., Shah, Aarti R., Gilmore, Petra, Davis, Alan E., Roe, Catherine M., Peskind, Elaine R., Li, Ge, Galasko, Douglas R., Clark, Christopher M., Quinn, Joseph F., Kaye, Jeffrey A., Morris, John C., Holtzman, David M., Townsend, R. Reid, Fagan, Anne M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Public Library of Science 2011
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020224/
https://ncbi.nlm.nih.gov/pubmed/21264269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0016032
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg